Ignite Creation Date:
2024-05-05 @ 10:30 PM
Last Modification Date:
2024-10-26 @ 10:20 AM
Study NCT ID:
NCT01124864
Status:
COMPLETED
Last Update Posted:
2016-03-02
First Post:
2010-05-14
Brief Title:
A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
A Phase II Multi-center Open-label Study of AUY922 Administered IV on a Once-weekly Schedule in Patients With Advanced Non-small-cell Lung Cancer Who Have Received at Least Two Lines of Prior Chemotherapy
Status:
COMPLETED
Status Verified Date:
2016-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will assess the efficacy of AUY922 when administered weekly at 70 mgm2 in adult patients with advanced Non-small-cell Lung Cancer NSCLC who have received at least two prior lines of chemotherapy Patients will be retrospectively and prospectively stratified based on their molecular tumor etiology The following strata was assigned Patients with Epidermal growth factor receptor EGFR activating mutations Patients with Kirstin Raus sarcoma virus KRAS activating mutations Patients with EML4-ALK anaplastic lymphoma kinase translocations and patients that were both EGFR and Kras wild type
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2010-020116-11 | EUDRACT_NUMBER | None | None |